JP6195384B2 - 乳癌の処置方法 - Google Patents

乳癌の処置方法 Download PDF

Info

Publication number
JP6195384B2
JP6195384B2 JP2014528678A JP2014528678A JP6195384B2 JP 6195384 B2 JP6195384 B2 JP 6195384B2 JP 2014528678 A JP2014528678 A JP 2014528678A JP 2014528678 A JP2014528678 A JP 2014528678A JP 6195384 B2 JP6195384 B2 JP 6195384B2
Authority
JP
Japan
Prior art keywords
treatment
entinostat
use according
exemestane
protein lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014528678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525465A5 (enExample
JP2014525465A (ja
Inventor
グッデナウ，ロバート
オルデントリッヒ，ピーター
Original Assignee
シンダックス ファーマシューティカルズ，インク．
シンダックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6195384(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シンダックス ファーマシューティカルズ，インク．, シンダックス ファーマシューティカルズ，インク． filed Critical シンダックス ファーマシューティカルズ，インク．
Publication of JP2014525465A publication Critical patent/JP2014525465A/ja
Publication of JP2014525465A5 publication Critical patent/JP2014525465A5/ja
Application granted granted Critical
Publication of JP6195384B2 publication Critical patent/JP6195384B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014528678A 2011-09-02 2012-08-31 乳癌の処置方法 Expired - Fee Related JP6195384B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161530873P 2011-09-02 2011-09-02
US61/530,873 2011-09-02
US201161532534P 2011-09-08 2011-09-08
US61/532,534 2011-09-08
US201161628999P 2011-11-12 2011-11-12
US61/628,999 2011-11-12
US201161568110P 2011-12-07 2011-12-07
US61/568,110 2011-12-07
PCT/US2012/053551 WO2013033656A1 (en) 2011-09-02 2012-08-31 Methods for the treatment of breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017084847A Division JP2017149761A (ja) 2011-09-02 2017-04-21 乳癌の処置方法

Publications (3)

Publication Number Publication Date
JP2014525465A JP2014525465A (ja) 2014-09-29
JP2014525465A5 JP2014525465A5 (enExample) 2015-11-05
JP6195384B2 true JP6195384B2 (ja) 2017-09-13

Family

ID=47756940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014528678A Expired - Fee Related JP6195384B2 (ja) 2011-09-02 2012-08-31 乳癌の処置方法
JP2017084847A Pending JP2017149761A (ja) 2011-09-02 2017-04-21 乳癌の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017084847A Pending JP2017149761A (ja) 2011-09-02 2017-04-21 乳癌の処置方法

Country Status (15)

Country Link
US (2) US10226472B2 (enExample)
EP (2) EP3381454A1 (enExample)
JP (2) JP6195384B2 (enExample)
KR (1) KR101956861B1 (enExample)
CN (3) CN103906837A (enExample)
AU (2) AU2012301616B2 (enExample)
BR (1) BR112014005080A2 (enExample)
CA (1) CA2847348A1 (enExample)
EA (1) EA201201474A1 (enExample)
ES (1) ES2663407T3 (enExample)
GE (1) GEP201706612B (enExample)
HK (1) HK1254859A1 (enExample)
MX (1) MX358254B (enExample)
UA (6) UA124241U (enExample)
WO (1) WO2013033656A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP201706612B (en) 2011-09-02 2017-02-10 Novamedica Llc Methods for the treatment of breast cancer
CN105492007A (zh) * 2013-05-03 2016-04-13 欣达克斯制药公司 癌症治疗方法
US20180104232A1 (en) * 2015-03-12 2018-04-19 The University Of Chicago Methods for determining prognosis for breast cancer patients
KR20240017973A (ko) * 2015-09-02 2024-02-08 신닥스 파마슈티컬스, 인크. 조합 요법을 위한 환자의 선별
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
CN112513636A (zh) 2018-05-07 2021-03-16 赛达克斯制药股份有限公司 用于组合疗法的患者的选择
KR102212699B1 (ko) 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20100092992A1 (en) * 2006-08-17 2010-04-15 Peter Hornbeck Lysine acetylation sites
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
CN103476430A (zh) 2011-02-02 2013-12-25 霍夫曼-拉罗奇有限公司 抗egfl7抗体用于治疗的给药
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
GEP201706612B (en) 2011-09-02 2017-02-10 Novamedica Llc Methods for the treatment of breast cancer
CH706458B1 (fr) 2012-04-30 2017-05-15 Granit Tech Sa Procédé de cimentation pour le stockage de déchets.

Also Published As

Publication number Publication date
JP2017149761A (ja) 2017-08-31
AU2012301616B2 (en) 2018-02-08
CN107982270A (zh) 2018-05-04
CA2847348A1 (en) 2013-03-07
WO2013033656A1 (en) 2013-03-07
AU2012301616A1 (en) 2014-04-17
UA124240U (uk) 2018-03-26
ES2663407T3 (es) 2018-04-12
UA123212U (uk) 2018-02-26
EA201201474A1 (ru) 2013-08-30
HK1254859A1 (zh) 2019-07-26
KR20140108629A (ko) 2014-09-12
UA149007U (uk) 2021-10-13
AU2018203059A1 (en) 2018-05-17
MX2014002515A (es) 2015-05-07
UA124238U (uk) 2018-03-26
CN103906837A (zh) 2014-07-02
MX358254B (es) 2018-08-10
EP2751267A1 (en) 2014-07-09
JP2014525465A (ja) 2014-09-29
UA124239U (uk) 2018-03-26
EP3381454A1 (en) 2018-10-03
UA124241U (uk) 2018-03-26
US20140378420A1 (en) 2014-12-25
EP2751267B1 (en) 2018-01-24
EP2751267A4 (en) 2015-01-07
GEP201706612B (en) 2017-02-10
US10226472B2 (en) 2019-03-12
CN114053284A (zh) 2022-02-18
US20190343844A1 (en) 2019-11-14
BR112014005080A2 (pt) 2017-03-28
KR101956861B1 (ko) 2019-03-12

Similar Documents

Publication Publication Date Title
US20190343844A1 (en) Methods for the treatment of breast cancer
US20240398944A1 (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
JP6860949B2 (ja) 癌の処置方法
JP2018519335A (ja) がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
KR20180095586A (ko) 난소암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
KR20180048703A (ko) 조합 요법을 위한 환자의 선별
RU2796903C2 (ru) Комбинация ингибитора hdac и анти-pd-1 антитела для лечения рака
UA144014U (uk) Набір для лікування стійкого до інгібітора ароматази раку молочної залози
HK1250142B (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170421

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170810

R150 Certificate of patent or registration of utility model

Ref document number: 6195384

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees